


BRAF AGNOSTIC, ARMS BALANCED FOR BRAF MUTATIONAL STATUS AND OTHER FACTORS

Ф

 \bigoplus





Treatments "graduating" from MICAT are recommended for advancement for Phase III evaluation. Each recommendation includes biomarker characterization

New treatment arms are added.

Treatments arms that do not extend progression free survival will be halted after dosing a minimum number of patients, reducing patient and systemic burden

Biomarker signatures from all patients will be monitored and correlated with clinical endpoints and response patterns

> Patients whose disease progresses will be eligible for re-randomization onto MICAT; they will have an increased chance of being allocated to a better performing treatment arm.

PD(L)1+ Second Generation Checkpoint Inhibitor

PD1 + Second Generation Checkpoint Inhibitor





PEP:

mPFS: ≥15mo.

Generate CTL response

Next-generation IL-2

de novo

HDAC

Oncolytic virus



SEP:

ORR: 55%



Off-the-shelf

Interferon-a

IL-15

antigen vaccine



G3/4:

AE < 60%

Investigate efficacy of second generation checkpoint inhibitors

Investigate efficacy of activators of

immune response

ACCEPTS ALL PATIENTS

PEP: mPFS: ≥15mo.

SEP: ORR: 55%

G3/4: AE < 40%

■ LAG-3

4-1BB

B7-H3

ACCEPTS ALL PATIENTS

IDO inhibitors (SFR1

0X40

Galectin

KIR CFA-

CAM CD27

GITR



MUTATIONAL STATUS BRAF WT embrolizumab pembrolizumab nivolumab nivolumab nivolumab -ipilimumab B PD1+CTLA4 D PD1+CTLA4 nivolumab +